There is strong evidence for benefit of apelin receptor agonists in pulmonary arterial hypertension and chronic kidney disease with further potential in heart failure as apelin promotes inotropy and has anti-fibrotic and antiplatelet actions. The gene discussed is APLN; the disease is chronic kidney disease.